What the FDA labels say about taking them together
Deferasirox and repaglinide
Deferasirox's FDA label of January 28, 2026 names repaglinide in its drug interactions section, and repaglinide's label names deferasirox too. The repaglinide label: “… are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.”
Check it at the source: the deferasirox FDA label on DailyMed (effective January 28, 2026, Novartis Pharmaceuticals Corporation); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).
What does the deferasirox label say about repaglinide?
Deferasirox label, drug interactionsDRUG INTERACTIONS Do not take Exjade with aluminum-containing antacid preparations. ( 7.1 ) Exjade increases the exposure of the CYP2C8 substrate repaglinide.
Jadenu label (Novartis Pharmaceuticals Corporation, January 26, 2018), drug interactionsDRUG INTERACTIONS Avoid the use of JADENU with aluminum-containing antacid preparations. ( 7.1 ) Deferasirox increases the exposure of repaglinide.
Source: FDA drug label (Jadenu, NDA206910), Novartis Pharmaceuticals Corporation, effective December 11, 2025 (SPL set fee89140-fff1-4443-9f42-24ac004fcda1), via openFDA
Source: FDA drug label (Jadenu, NDA207968), Novartis Pharmaceuticals Corporation, effective January 26, 2018 (SPL set 87f79cd1-2799-478f-a591-85d20c44f207), via openFDA
Source: FDA drug label (Exjade), Novartis Pharmaceuticals Corporation, effective January 28, 2026 (SPL set 3495a70c-870c-4968-940e-8baea152cf85), via openFDA; the full label on DailyMed
What does the repaglinide label say about deferasirox?
Repaglinide label, drug interactionsCYP2C8 and CYP3A4 Inhibitors Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co-administered. Examples: Drugs that are known to inhibit CYP3A4 include antifungal agents (ketoconazole, itraconazole) and antibacterial agents (clarithromycin, erythromycin). Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.
Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Deferasirox | Repaglinide | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.25 per tablet 360 mg tablet | $0.0987 per tablet 1 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once